Oct 6, 2025Journal ArticleFibroblasts Are the Primary Contributors to a Disrupted Micro-Environment in End-Stage Pediatric Hypertrophic Cardiomyopathy.Written by 1 Roon author & 6 others Via The American Heart Association Journals
Nov 3, 2025Journal ArticlePrecision Medicine and the FDA Modernization Act 2.0: Catalyzing Innovation in Cardiovascular Therapy.Written by 1 Roon author & 4 others Via The American Heart Association Journals
ResearchActivated fibroblasts drive cellular interactions in end-stage pediatric hypertrophic cardiomyopathy
ResearchLeft ventricular non-compaction in paediatrics: a novel semi-automated imaging technique bridging imaging findings and clinical outcomes
ResearchAssessment of parental decision making in congenital heart disease, cardiomyopathy and heart transplantation: an observational study analysing decisional characteristics and preferences
ResearchA Good Death: Role of Shared Decision Making and Palliative Care in Children with Cardiac Disease
ResearchA Web-Based Precision Medicine Tool for Predicting Variant Pathogenicity in Cardiomyopathy- and Channelopathy-Associated Genes
ResearchJunctional Ectopic Tachycardia Caused by Junctophilin-2 Expression Silencing Is Selectively Sensitive to Ryanodine Receptor Blockade
ResearchBalloon-Expandable Valve for Treatment of Evolut Valve Failure: Implications on Neoskirt Height and Leaflet Overhang
ResearchSignal-to-Noise Analysis Can Inform the Likelihood That Incidentally Identified Variants in Sarcomeric Genes Are Associated with Pediatric Cardiomyopathy
ResearchArrhythmogenic cardiomyopathy is under-recognized in end-stage pediatric heart failure: A 36-year single-center experience
ResearchRisk factors associated with post-transplant superior caval vein stenosis in paediatric heart transplantation